N-(2-氯乙基)-N-乙基-2-溴苄基胺 | 62078-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氯乙基)-N-乙基-2-溴苄基胺
• 英文名称: DSP 4
• 英文别名: N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine；Benzenemethanamine, 2-bromo-N-(2-chloroethyl)-N-ethyl-；N-[(2-bromophenyl)methyl]-2-chloro-N-ethylethanamine
• CAS: 62078-98-2
• 化学式: C₁₁H₁₅BrClN
• 分子量: 276.604
• InChiKey: SDJLVPMBBFRBLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为产物：
  描述：

  N-(2-hydroxyethyl)-N-ethyl-2-bromobenzylamine 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 以71%的产率得到N-(2-氯乙基)-N-乙基-2-溴苄基胺
  参考文献：
  名称：

  Radioiodinated analogs of xylamine: N-(2-chloroethyl)-N-ethyl-2-[125I]iodobenzylamine and N,N-diethyl-2-[125I]iodobenzylamine as potential tools for monoamine uptake exploration by spect

  摘要：

  为了改进神经内分泌肿瘤的闪烁成像和放射治疗，我们合成了两种放射性碘化苄胺[N-（2-氯乙基）-N-乙基-2-[125I]碘苄胺和 N,N-二乙基-2-[125I]碘苄胺]，它们是二甲胺[N-（2-氯乙基）-N-乙基-2-甲基苄胺]的类似物。二甲胺是去甲肾上腺素摄取和蓄积的不可逆抑制剂。我们合成并纯化了两种未标记的碘化衍生物[N-（2-氯乙基）-N-乙基-2-碘苄胺和 N,N-二乙基-2-碘苄胺]，并通过高效液相色谱法、核磁共振法和质谱法对其进行了检测。体外用[3H]尼索西汀测定了它们对大鼠脑膜匀浆中去甲肾上腺素转运体的亲和力。放射性碘化是通过碘化物与溴化前体的亲核交换进行的。N,N-二乙基-2-[125I]碘苄胺是直接从 N,N-二乙基-2-溴苄胺中获得的。N-(2-氯乙基)-N-乙基-2-[125I]碘苄胺的放射合成需要三个步骤。我们合成了一种新的溴化前体[N-乙基-N-(2-溴苄基)甘氨酸乙酯]，它对放射性标记稳定，适合还原成 N-(2-羟乙基)-N-辛基-2-[125I]碘苄胺。在过量亚硫酰氯的存在下，N-(2-羟乙基)-N-乙基-2-[125I]碘苄胺转化为 N-(2-氯乙基)-N-乙基-2-[125I]碘苄胺。放射性碘化衍生物经高效液相色谱法纯化和检测。

  DOI：

  10.1002/jlcr.2580360711

文献信息

• METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR
  申请人：Shamloo Mehrdad

  公开号：US20160184315A1

  公开（公告）日：2016-06-30

  A β 1 -ADR agonist prodrug compound, which is hydrolysable in vivo to release a β1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the β1-ADR agonist compound.

  一种β1-ADR激动剂前药化合物，其在体内可水解释放出β1-ADR激动剂化合物，该前药化合物含有一种基团，相对于β1-ADR激动剂化合物，赋予前药化合物更大的亲脂性和中枢神经系统生物利用度。
• IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
  申请人：Bondy Steven S.

  公开号：US20100028301A1

  公开（公告）日：2010-02-04

  The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.

  本发明涉及一种制备用于治疗或预防病毒感染的药物组合物，其包含至少一种咪唑并[4,5-c]吡啶前药作为活性成分，其通式为（A），其中取代基在规范中描述。该发明还涉及根据上述通式制备和筛选化合物的方法以及它们在治疗或预防病毒感染中的应用。
• LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION
  申请人：MERCATOR MEDSYSTEMS, INC.

  公开号：US20130252932A1

  公开（公告）日：2013-09-26

  Pharmaceutical preparations, compositions, systems, and devices including medical devices and diagnostic or therapeutic agents, and methods to treat disease by modification of local tissue environment to modulate the therapeutic index of locally or systemically delivered therapeutic or diagnostic agents. Improved ability to reduce sympathetic nerve activity in the adventitia and perivascular tissues around arteries and veins in the body. Modulation of the local tissue environment around an artery to enable more effective denervation with or without a therapeutic agent. Modulation may include adjustment of the pH of the tissue.

  制药制剂、组成物、系统和设备，包括医疗设备和诊断或治疗剂，以及通过改变局部组织环境来调节局部或全身输送的治疗或诊断剂来治疗疾病的方法。改善了在体内动脉和静脉周围的外膜和周围组织中降低交感神经活动的能力。调节动脉周围的局部组织环境，以便更有效地进行去神经化治疗，可以带或不带治疗剂。调节可以包括调整组织的pH值。
• Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
  申请人：Puerstinger Gerhard

  公开号：US20090208456A1

  公开（公告）日：2009-08-20

  The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

  本发明涉及制备用于治疗或预防病毒感染的药物组合物，其中至少包括一种具有通式（A）的咪唑并[4,5-c]嘧啶类活性成分，其中取代基如规范所述。本发明还涉及制备符合上述通式的化合物的过程，其药学上可接受的配方以及它们作为药物或用于治疗或预防病毒感染的用途。
• DISEASE ANIMAL MODEL FOR CHRONIC PAIN
  申请人：Astellas Pharma Inc.

  公开号：EP2327299A1

  公开（公告）日：2011-06-01

  A disease animal model, characterized in that a chronic pain is induced by applying a treatment for reducing the biogenic amine level to a mammal, and a method for screening for a therapeutic agent for a chronic pain, characterized in that a test substance is administered to said disease animal model.

  一种疾病动物模型，其特征在于通过对哺乳动物施用降低生物胺水平的治疗诱发慢性疼痛，以及一种筛选慢性疼痛治疗剂的方法，其特征在于对所述疾病动物模型施用试验物质。